MNKD 2018 Proxy Statement

EXECUTIVE OFFICERS OF THE REGISTRANT The following table sets forth our current executive officers and their ages: Name Age Position(s) Michael E. Castagna, Pharm.D. . . . . 41 Chief Executive Officer and Director Steven B. Binder . . . . . . . . . . . . . . . . 55 Chief Financial Officer David Kendall, M.D. . . . . . . . . . . . . . 57 Chief Medical Officer Joseph Kocinsky . . . . . . . . . . . . . . . . 54 Chief Technology Officer Patrick McCauley . . . . . . . . . . . . . . . 53 Chief Commercial Officer David B. Thomson, Ph.D., J.D. . . . . 51 General Counsel and Secretary Stuart A. Tross, Ph.D. . . . . . . . . . . . . 51 Chief People and Workplace Officer Rosabel R. Alinaya . . . . . . . . . . . . . . 57 Senior Vice President, Investor Relations and Treasury Courtney Barton . . . . . . . . . . . . . . . . 35 Vice President, Chief Compliance and Privacy Officer Michael E. Castagna, Pharm.D. has served as our Chief Executive Officer and as one of our directors since May 2017. Mr. Castagna also served as our Chief Commercial Officer from March 2016 until May 2017. From November 2012 until he joined the Company, Mr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit. From 2010 to 2012, he was Executive Director, Immunology, at Bristol- Myers Squibb Co. Before BMS, Mr. Castagna served as Vice President & Head, Biopharmaceuticals, North America, at Sandoz. He has also held positions with commercial responsibilities at EMD (Merck) Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from University of the Sciences- Philadelphia College of Pharmacy, a Doctor of Pharmacy from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania. Steven B. Binder has been our Chief Financial Officer since July 2017. Prior to joining us, Mr. Binder was at Stryker Corporation, where he served as Vice President and Chief Financial Officer for Stryker’s International Group, based in Singapore. Prior to Stryker, Mr. Binder served in a series of senior leadership roles at Bristol- Myers Squibb Company, as Vice President, Finance over different geographic operating units: United States (2012-2013), Europe (2008-2011), AsiaPacific (2005-2007), and Japan (2003-2005). Prior to his international roles at Bristol-Myers Squibb, Mr. Binder served in three senior leadership roles for Oncology Therapeutics Network, a U.S. based independent subsidiary of BMS: Vice President, Strategic Development from 2001 through 2003, Vice President, Customer Operations from 2000 through 2001, and Chief Financial Officer from 1997 through 2000. Before OTN, Mr. Binder progressed through three finance and accounting roles for BMS Worldwide Medicines Group after joining the company in 1992. Mr. Binder also was with Deloitte & Touche from 1984 through 1992. Mr. Binder received a B.S. degree in Accounting and Business Administration from Muhlenberg College and is a Certified Public Accountant. David Kendall, M.D. has been our Chief Medical Officer since February 2018. Dr. Kendall has over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy. Prior to joining us, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and led all medical affairs activities and guided research and development strategy across multiple geographies. Prior to Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals. Dr. Kendall received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College. Joseph Kocinsky has been our Chief Technology Officer since October 2015 . Mr. Kocinsky has over 28 years of experience in the pharmaceutical industry in technical operations and product development. Prior to 42